Bliss Cunningham

Elemental Therapeutics 
The University of Melbourne, VIC  
 
At Elemental Therapeutics, we’re on a mission to restore the efficacy of antibiotics against drug-resistant infections.  
 
We’re developing a small molecule therapeutic called PBT2, for treatment of community-acquired bacterial pneumonia (CABP). PBT2 is safe, cheap, orally bio-available and has shown no development of resistance. We are working to take PBT2 through clinical trials and get it to patients by 2033.